{
    "data": [
        {
            "id": "3756696",
            "type": "article",
            "attributes": {
                "publishOn": "2015-12-16T11:16:02-05:00",
                "isLockedPro": false,
                "commentCount": 21,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Humira: Will AbbVie's Patents Keep Out Biosimilars For Its TNF-Blocker Blockbuster?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "49101",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "167088",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/3756696-humira-will-abbvies-patents-keep-out-biosimilars-for-tnf-blocker-blockbuster"
            }
        },
        {
            "id": "3756826",
            "type": "article",
            "attributes": {
                "publishOn": "2015-12-15T11:37:51-05:00",
                "isLockedPro": false,
                "commentCount": 11,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie Stock Has Been Made Cheap By Exaggerated Patent-Related Concerns",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "48221",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "167091",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3756826-abbvie-stock-made-cheap-exaggerated-patent-related-concerns"
            }
        },
        {
            "id": "3741186",
            "type": "article",
            "attributes": {
                "publishOn": "2015-12-08T11:56:58-05:00",
                "isLockedPro": false,
                "commentCount": 17,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Buy AbbVie Inc. For Both The Dividend And Growth",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "92086",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3741186-buy-abbvie-inc-for-dividend-and-growth"
            }
        },
        {
            "id": "3716086",
            "type": "article",
            "attributes": {
                "publishOn": "2015-11-27T02:15:23-05:00",
                "isLockedPro": false,
                "commentCount": 49,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Amgen Invites AbbVie To Dance For Humira Biosimilar",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "21877",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3716086-amgen-invites-abbvie-to-dance-for-humira-biosimilar"
            }
        },
        {
            "id": "3671146",
            "type": "article",
            "attributes": {
                "publishOn": "2015-11-10T09:31:39-05:00",
                "isLockedPro": false,
                "commentCount": 35,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie Is Well Poised For Continued Outperformance",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25562",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "165272",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3671146-abbvie-is-well-poised-for-continued-outperformance"
            }
        },
        {
            "id": "3634426",
            "type": "article",
            "attributes": {
                "publishOn": "2015-11-02T16:43:34-05:00",
                "isLockedPro": false,
                "commentCount": 17,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Read My Lips: No Humira Biosimilars Until 2022",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "21877",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3634426-read-lips-no-humira-biosimilars-until-2022"
            }
        },
        {
            "id": "3627096",
            "type": "article",
            "attributes": {
                "publishOn": "2015-10-30T14:52:23-04:00",
                "isLockedPro": false,
                "commentCount": 40,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie Lays Out ItS Game Plan. Stock Soars, More Gains Ahead",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23762",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "164703",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3627096-abbvie-lays-out-game-plan-stock-soars-gains-ahead"
            }
        },
        {
            "id": "3623506",
            "type": "article",
            "attributes": {
                "publishOn": "2015-10-29T21:23:11-04:00",
                "isLockedPro": false,
                "commentCount": 48,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Sciences Confirms The Bullish Case On AbbVie",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25562",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "164646",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3623506-gilead-sciences-confirms-bullish-case-on-abbvie"
            }
        },
        {
            "id": "3600416",
            "type": "article",
            "attributes": {
                "publishOn": "2015-10-24T11:55:36-04:00",
                "isLockedPro": false,
                "commentCount": 22,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie - After 10% Drop, Is This The Right Time To Buy?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "80836",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "164295",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3600416-abbvie-after-10-percent-drop-is-this-right-time-to-buy"
            }
        },
        {
            "id": "3584976",
            "type": "article",
            "attributes": {
                "publishOn": "2015-10-20T09:12:14-04:00",
                "isLockedPro": false,
                "commentCount": 34,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bullish On AbbVie: Management Thinks They've An At Least $1 Billion A Year Product Coming",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24643",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "164038",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3584976-bullish-on-abbvie-management-thinks-least-1-billion-year-product-coming"
            }
        },
        {
            "id": "3540396",
            "type": "article",
            "attributes": {
                "publishOn": "2015-09-30T13:42:55-04:00",
                "isLockedPro": false,
                "commentCount": 15,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbvie Inc Deserves A Chance",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "39141",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3540396-abbvie-inc-deserves-chance"
            }
        },
        {
            "id": "3458516",
            "type": "article",
            "attributes": {
                "publishOn": "2015-08-21T13:37:30-04:00",
                "isLockedPro": false,
                "commentCount": 4,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Why Four Months Is Worth $350m To AbbVie And Filgotinib",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "21877",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3458516-why-four-months-is-worth-350m-to-abbvie-and-filgotinib"
            }
        },
        {
            "id": "3456706",
            "type": "article",
            "attributes": {
                "publishOn": "2015-08-20T22:29:15-04:00",
                "isLockedPro": false,
                "commentCount": 5,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Baxalta Vs. AbbVie: Biopharma Spin-Off Battle",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "63883",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3456706-baxalta-vs-abbvie-biopharma-spin-off-battle"
            }
        },
        {
            "id": "3448636",
            "type": "article",
            "attributes": {
                "publishOn": "2015-08-18T12:25:06-04:00",
                "isLockedPro": false,
                "commentCount": 24,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie: The Riskiest Dividend Aristocrat",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "63883",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3448636-abbvie-riskiest-dividend-aristocrat"
            }
        },
        {
            "id": "3376525",
            "type": "article",
            "attributes": {
                "publishOn": "2015-07-30T13:40:54-04:00",
                "isLockedPro": false,
                "commentCount": 5,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie Poised For Continued Success",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24491",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3376525-abbvie-poised-for-continued-success"
            }
        },
        {
            "id": "3363145",
            "type": "article",
            "attributes": {
                "publishOn": "2015-07-28T08:45:23-04:00",
                "isLockedPro": false,
                "commentCount": 14,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie: Viekira Pak Sales Not Likely To Hit $3 Billion Run Rate By Year End",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "53222",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3363145-abbvie-viekira-pak-sales-not-likely-to-hit-3-billion-run-rate-by-year-end"
            }
        },
        {
            "id": "3354325",
            "type": "article",
            "attributes": {
                "publishOn": "2015-07-24T08:12:42-04:00",
                "isLockedPro": false,
                "commentCount": 12,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Premarket Biotech Digest: The PCSK9 Race, AbbVie Earnings, Inotek Jumps 200%",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "53222",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/3354325-premarket-biotech-digest-the-pcsk9-race-abbvie-earnings-inotek-jumps-200-percent"
            }
        },
        {
            "id": "3345335",
            "type": "article",
            "attributes": {
                "publishOn": "2015-07-22T08:30:55-04:00",
                "isLockedPro": false,
                "commentCount": 22,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie Is At 52-Week Highs, But Is It A Buy?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "44001",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3345335-abbvie-is-at-52-week-highs-but-is-it-a-buy"
            }
        },
        {
            "id": "3293195",
            "type": "article",
            "attributes": {
                "publishOn": "2015-06-30T08:21:46-04:00",
                "isLockedPro": false,
                "commentCount": 12,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Premarket Biotech Digest: Celgene-Juno, AbbVie Rx Data, FDA-Gilead Lawsuit",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "53222",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3293195-premarket-biotech-digest-celgene-juno-abbvie-rx-data-fda-gilead-lawsuit"
            }
        },
        {
            "id": "3278995",
            "type": "article",
            "attributes": {
                "publishOn": "2015-06-23T16:01:58-04:00",
                "isLockedPro": false,
                "commentCount": 9,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie, Brightest Outlook In The Sector",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "67775",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3278995-abbvie-brightest-outlook-in-the-sector"
            }
        },
        {
            "id": "3275545",
            "type": "article",
            "attributes": {
                "publishOn": "2015-06-22T15:52:18-04:00",
                "isLockedPro": false,
                "commentCount": 15,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbvie's Core Portfolio And Sleepers To Bolster Sales Long-Term",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "89226",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "157507",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3275545-abbvies-core-portfolio-and-sleepers-to-bolster-sales-long-term"
            }
        },
        {
            "id": "3173166",
            "type": "article",
            "attributes": {
                "publishOn": "2015-05-13T07:02:41-04:00",
                "isLockedPro": false,
                "commentCount": 22,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pharmacyclics-AbbVie Merger Has Many Moving Parts",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "54792",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "155208",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3173166-pharmacyclics-abbvie-merger-has-many-moving-parts"
            }
        },
        {
            "id": "3157196",
            "type": "article",
            "attributes": {
                "publishOn": "2015-05-07T20:03:36-04:00",
                "isLockedPro": false,
                "commentCount": 3,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "A Comprehensive Look At AbbVie's Competition Against Its Top 10 Products",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "75375",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3157196-a-comprehensive-look-at-abbvies-competition-against-its-top-10-products"
            }
        },
        {
            "id": "3123876",
            "type": "article",
            "attributes": {
                "publishOn": "2015-05-01T15:29:28-04:00",
                "isLockedPro": false,
                "commentCount": 26,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie Clearance Sale Going On Now",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "40141",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "154585",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3123876-abbvie-clearance-sale-going-on-now"
            }
        },
        {
            "id": "3110726",
            "type": "article",
            "attributes": {
                "publishOn": "2015-04-28T12:12:21-04:00",
                "isLockedPro": false,
                "commentCount": 5,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie Pushing Hepatitis C Pipeline, But Is It Fast Enough?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "75375",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3110726-abbvie-pushing-hepatitis-c-pipeline-but-is-it-fast-enough"
            }
        },
        {
            "id": "3085276",
            "type": "article",
            "attributes": {
                "publishOn": "2015-04-22T08:49:39-04:00",
                "isLockedPro": false,
                "commentCount": 20,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Sciences Vs. AbbVie: Which Is A Better Buy?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23452",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3085276-gilead-sciences-vs-abbvie-which-is-a-better-buy"
            }
        },
        {
            "id": "3068466",
            "type": "article",
            "attributes": {
                "publishOn": "2015-04-14T07:15:22-04:00",
                "isLockedPro": false,
                "commentCount": 50,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie: Great Growth, Great Value, And A 3.3% Dividend",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "21305",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3068466-abbvie-great-growth-great-value-and-a-3_3-percent-dividend"
            }
        },
        {
            "id": "3059926",
            "type": "article",
            "attributes": {
                "publishOn": "2015-04-09T12:55:31-04:00",
                "isLockedPro": false,
                "commentCount": 60,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Mr. Valuation Thinks AbbVie Will 'Humira' Us For A Few More Years",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23179",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/3059926-mr-valuation-thinks-abbvie-will-humira-us-for-a-few-more-years"
            }
        },
        {
            "id": "3048596",
            "type": "article",
            "attributes": {
                "publishOn": "2015-04-02T16:42:34-04:00",
                "isLockedPro": false,
                "commentCount": 35,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie: Is There Enough Time To Promote New Drugs Before Humira Patent Expired?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "81316",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "153205",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3048596-abbvie-is-there-enough-time-to-promote-new-drugs-before-humira-patent-expired"
            }
        },
        {
            "id": "3000866",
            "type": "article",
            "attributes": {
                "publishOn": "2015-03-14T07:01:58-04:00",
                "isLockedPro": false,
                "commentCount": 77,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Is The Jury Ready? Time To Evaluate AbbVie Post-Spinoff",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24787",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3000866-is-the-jury-ready-time-to-evaluate-abbvie-post-spinoff"
            }
        },
        {
            "id": "2995396",
            "type": "article",
            "attributes": {
                "publishOn": "2015-03-12T10:11:28-04:00",
                "isLockedPro": false,
                "commentCount": 16,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Does AbbVie's Acquisition Of Pharmacyclics Make Cents?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "32121",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "152031",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2995396-does-abbvies-acquisition-of-pharmacyclics-make-cents"
            }
        },
        {
            "id": "2988116",
            "type": "article",
            "attributes": {
                "publishOn": "2015-03-10T09:12:53-04:00",
                "isLockedPro": false,
                "commentCount": 33,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "The Pharmacyclics And AbbVie Deal Is Good For No One",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "80646",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2988116-the-pharmacyclics-and-abbvie-deal-is-good-for-no-one"
            }
        },
        {
            "id": "2984546",
            "type": "article",
            "attributes": {
                "publishOn": "2015-03-09T08:35:32-04:00",
                "isLockedPro": false,
                "commentCount": 24,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie's Stock Now Has A Lot To Gain",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "80676",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "151775",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2984546-abbvies-stock-now-has-a-lot-to-gain"
            }
        },
        {
            "id": "2977006",
            "type": "article",
            "attributes": {
                "publishOn": "2015-03-06T14:01:28-05:00",
                "isLockedPro": false,
                "commentCount": 36,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Acquisition Boosts AbbVie's Long Term Prospects",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23762",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "151650",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2977006-acquisition-boosts-abbvies-long-term-prospects"
            }
        },
        {
            "id": "2975616",
            "type": "article",
            "attributes": {
                "publishOn": "2015-03-05T07:27:39-05:00",
                "isLockedPro": false,
                "commentCount": 34,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie Buys Pharmacyclics: The Story Is Likely Far From Over",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "80676",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "151617",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2975616-abbvie-buys-pharmacyclics-the-story-is-likely-far-from-over"
            }
        },
        {
            "id": "2940446",
            "type": "article",
            "attributes": {
                "publishOn": "2015-02-24T09:39:25-05:00",
                "isLockedPro": false,
                "commentCount": 38,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie: Attractive Valuation, Growth Prospects & Yield",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23762",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "151107",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2940446-abbvie-attractive-valuation-growth-prospects-and-yield"
            }
        },
        {
            "id": "2943766",
            "type": "article",
            "attributes": {
                "publishOn": "2015-02-24T08:21:56-05:00",
                "isLockedPro": false,
                "commentCount": 15,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbvie's 'One Trick Pony' Faces Patent Expiration In 2016",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "31441",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2943766-abbvies-one-trick-pony-faces-patent-expiration-in-2016"
            }
        },
        {
            "id": "2873966",
            "type": "article",
            "attributes": {
                "publishOn": "2015-02-03T09:31:33-05:00",
                "isLockedPro": false,
                "commentCount": 21,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie Inc. Earnings Reported: Where Do We Go From Here?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "79355",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "149990",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2873966-abbvie-inc-earnings-reported-where-do-we-go-from-here"
            }
        },
        {
            "id": "2875066",
            "type": "article",
            "attributes": {
                "publishOn": "2015-02-02T13:26:43-05:00",
                "isLockedPro": false,
                "commentCount": 13,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie Projects $3B Sales For HCV Cocktail, But Shares Fall 3%",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "31441",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2875066-abbvie-projects-3b-sales-for-hcv-cocktail-but-shares-fall-3-percent"
            }
        },
        {
            "id": "2868436",
            "type": "article",
            "attributes": {
                "publishOn": "2015-01-30T09:10:04-05:00",
                "isLockedPro": false,
                "commentCount": 42,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie's Viekira Pak Has Caught Everyone's Attention",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24491",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2868436-abbvies-viekira-pak-has-caught-everyones-attention"
            }
        },
        {
            "id": "2867656",
            "type": "article",
            "attributes": {
                "publishOn": "2015-01-30T02:13:00-05:00",
                "isLockedPro": false,
                "commentCount": 15,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie Earnings Preview: HCV Cocktail In Focus",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "31441",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2867656-abbvie-earnings-preview-hcv-cocktail-in-focus"
            }
        },
        {
            "id": "2850876",
            "type": "article",
            "attributes": {
                "publishOn": "2015-01-27T15:15:38-05:00",
                "isLockedPro": false,
                "commentCount": 7,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie Inc.: Another Stock Pick For 2015",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "79355",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "149570",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2850876-abbvie-inc-another-stock-pick-for-2015"
            }
        },
        {
            "id": "2831046",
            "type": "article",
            "attributes": {
                "publishOn": "2015-01-21T02:24:38-05:00",
                "isLockedPro": false,
                "commentCount": 26,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie Provides Outlook For 2015: Let's Analyze It",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23452",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "149104",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2831046-abbvie-provides-outlook-for-2015-lets-analyze-it"
            }
        },
        {
            "id": "2814425",
            "type": "article",
            "attributes": {
                "publishOn": "2015-01-12T14:46:51-05:00",
                "isLockedPro": false,
                "commentCount": 66,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbvie Retreats On Gilead, Anthem Deal. Buying Opportunity?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "31441",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2814425-abbvie-retreats-on-gilead-anthem-deal-buying-opportunity"
            }
        },
        {
            "id": "2794165",
            "type": "article",
            "attributes": {
                "publishOn": "2015-01-02T15:55:57-05:00",
                "isLockedPro": false,
                "commentCount": 6,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie Has Some Excellent Entries In Rheumatoid Arthritis",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "75375",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "148096",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2794165-abbvie-has-some-excellent-entries-in-rheumatoid-arthritis"
            }
        }
    ]
}